65,437 trials
Chronic Kidney Disease
Primary: Geometric Mean Ratio of Maximum Observed Plasma Peak Concentration (Cmax) for Verinurad — 13.30; 33.96; 26.09 ng/mL
Opioid Dependence
Primary: Study Enrollment — 7 Participants
Trichotillomania
Primary: Percentage of Participants in the HabitAware Condition That Wore the Device for 6 Hours Per Day and More Than 4 Days Per Week. — 9; 0 Participants
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Healthy
Primary: Period 1 and Period 2, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) Within 1 Dosing Interval (AUC[0-tau]) of Ethinylestradiol (EE) — 966…
Psoriasis
Primary: Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin. — 4; 14; 26; 44 Participants
Peripheral Neuropathy
Primary: Number of Participants With Greater Than 50% Compliance to Exercise Regimen — 0 Participants
Non-infectious Anterior Uveitis
Primary: Anterior Chamber Cell Grade at Week 8 — -0.7; -0.9; -0.5 units on a scale
Malaria,Falciparum
Primary: Number and Severity of Adverse Events After TB31F Administration — 0; 1; 1; 0 Participants
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Influenza Virus
Primary: Efficacy Endpoint: First-Occurrence Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Confirmed Influenza A and/or B of Any Influenza Strain in Subjects ≥6 to <72…
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 8.38; 7.33 Months
Asthma
Primary: Change in Tolerance to Inhaled Methacholine — 5.3; 24.2 mg/ml
Severe Acute Respiratory Syndrome Coronavirus 2 · COVID-19
Primary: Time to Hospital Discharge — 7.0; 8.0 days — p=0.509
Cigarette Smoking
Primary: Percent of Participants Completing Intervention Period — 25; 31 Participants